To figure out the association between HER2 amplification and other non–PD-L1 immune checkpoints in BRCA, LUAD and STAD patients, we next exploit RNA-seq data to depict the expression levels of 7 key immune checkpoints. This evidence concerns the gene ERBB2 and gastric adenocarcinoma.